NasdaqGM - Delayed Quote • USD
Avidity Biosciences, Inc. (RNA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | -0.78 | -0.78 | -3.2 | -3.53 |
| Low Estimate | -0.95 | -0.99 | -4.19 | -4.65 |
| High Estimate | -0.67 | -0.67 | -2.71 | -2.76 |
| Year Ago EPS | -0.74 | -0.66 | -2.91 | -3.2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 5 | 5 |
| Avg. Estimate | 2.93M | 2.81M | 10.24M | 7M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 7.09M | 7.09M | 21.2M | 15M |
| Year Ago Sales | 2.23M | 2.14M | 9.56M | 10.24M |
| Sales Growth (year/est) | 31.20% | 31.30% | 7.10% | -31.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.85 | -0.8 | -0.77 | -0.66 |
| EPS Actual | -0.74 | -0.66 | -0.71 | -0.79 |
| Difference | 0.11 | 0.14 | 0.06 | -0.13 |
| Surprise % | 12.90% | 17.50% | 7.80% | -19.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.78 | -0.78 | -3.2 | -3.53 |
| 7 Days Ago | -0.78 | -0.78 | -3.2 | -3.53 |
| 30 Days Ago | -0.78 | -0.78 | -3.2 | -3.53 |
| 60 Days Ago | -0.83 | -0.85 | -3.51 | -3.66 |
| 90 Days Ago | -0.83 | -0.85 | -3.51 | -3.66 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RNA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -5.40% | -- | -- | 6.50% |
| Next Qtr. | -18.20% | -- | -- | 12.00% |
| Current Year | -10.00% | -- | -- | 5.30% |
| Next Year | -10.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 3/14/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/5/2024 |
| Reiterates | Needham: Buy to Buy | 3/4/2024 |
| Reiterates | Needham: Buy to Buy | 2/29/2024 |
| Reiterates | Chardan Capital: Buy to Buy | 2/29/2024 |
Related Tickers
DYN Dyne Therapeutics, Inc.
24.73
+4.37%
FDMT 4D Molecular Therapeutics, Inc.
23.25
-1.19%
VERA Vera Therapeutics, Inc.
39.65
+2.48%
RVMD Revolution Medicines, Inc.
35.96
+1.78%
SANA Sana Biotechnology, Inc.
8.72
+2.59%
JANX Janux Therapeutics, Inc.
47.39
+0.62%
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
SRRK Scholar Rock Holding Corporation
14.53
+4.08%
KURA Kura Oncology, Inc.
19.65
+3.42%